CDH5 and neoplasm: Despite the observed increased cisplatin delivery to SCLC xenograft tumours with unperturbed VM (Fig. 8), there was decreased response to cisplatin and etoposide (Fig. 9) compared with that in the corresponding xenografts with reduced VE-cadherin expression and reduced VM.